This is a member-only event.
Tuesday, August 3
Tackling extensively drug-resistant TB (XDR-TB) through public-private partnerships
The talk will provide an overview of RTI’s work in the area of drug discovery, development, and approval. This will include RTI’s work on the BARDA program, CARB-X, and our most recent success, the approval of pretomanid. Pretomanic is a treatment for extensively drug-resistant TB (XDR-TB) and was developed by TB Alliance, a nonprofit public-private partnership that RTI helped to form in 2000. XDR-TB is a type of TB that is resistant to two of the four main drugs that are given for TB around the world, plus any fluoroquinolone and one or more of three injectable second-line drugs. We will share our journey and lessons learned.
Juliana Ruzante— Senior Food Safety and Public Health Specialist, RTI International
Juliana M. Ruzante, a public health veterinarian with 20 years of expertise in food safety and epidemiology of foodborne diseases, is a research public health analyst in RTI International’s Center for Health and Environmental Modeling where she develops strategies to expand RTI’s work in the area of food safety and antimicrobial resistance by fostering partnerships across institutes and organizations. She is responsible for identifying and pursuing new funding and research opportunities and also manages and provides technical advice to several projects in food safety, antimicrobial resistance, and public health. Dr. Ruzante has served on advisory committees, including the National Advisory Committee on Microbiological Criteria for Foods, the Food and Drug Administration’s Food Advisory Committee, as well as expert meetings organized by the National Academies, The Food and Agriculture Organization of the United Nations, and the World Health Organization. Dr. Ruzante is an adjunct assistant professor at the School of Public Health at San Diego State University.
Doris Rouse—Vice President, Global Health Technologies, RTI International
Dr. Doris Rouse is Vice President of RTI International’s Global Public Health Impact Center. She manages the application of diverse disciplines to address major global health needs. Her research interests focus on the development of new therapies to combat antimicrobial resistance. Dr. Rouse has been the Project Director for global health programs supporting a wide range of clients, including NIAID, NIDA, the Rockefeller Foundation, BARDA, industry and the Bill & Melinda Gates Foundation. She contributed to the formation of the Global Alliance for TB Drug Development (TB Alliance), an international public/private consortium to develop new drugs for tuberculosis, and she currently leads RTI’s work in support of the TB Alliance’s ongoing activities. She leads RTI’s activities in the BARDA CARB-X public-private collaboration to develop new solutions to combat antimicrobial resistant bacteria. Dr. Rouse is an Adjunct Professor at the University of North Carolina Gillings School of Public Health and served in the Peace Corps as a science teacher in Liberia.
Autumn Dove— PhD Student, Microbiology and Cell Science, University of Florida
Autumn is a third-year PhD student in the Microbiology and Cell Science Department at the University of Florida in Dr. Daniel Czyz’s lab. She graduated from Northern Arizona University with a BS in biology and a BA in Spanish. Her current research focus is using drug repurposing to modulate the host immune response against antimicrobial resistant infections to find novel therapeutics.
Registration runs through Tuesday, August 3, until the webinar begins.
Erica Hellmich | 515-294-3352 | email@example.com